Guardant Health slides as investors digest Q4 results and a risk-off tape

Guardant Health (GH) is down 8.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks tied to post-earnings positioning after the company’s late-last-week Q4 report, where strong revenue growth was paired with continued losses and elevated spending to scale its Shield screening launch. The broader market tone also appeared risk-off following fresh trade-policy headlines, which can amplify selloffs in higher-beta growth stocks.

Details:

In its February 19, 2026 earnings release, the company reported Q4 2025 revenue of $281.3 million (up 39% year over year), with Oncology revenue of $189.9 million and Screening revenue of $35.1 million.

The same release showed a non-GAAP net loss per share of $0.50 for the quarter and noted operating expenses rising year over year, driven largely by commercial expansion and marketing for Shield and other products.

Guardant guided 2026 revenue to $1.25–$1.28 billion, while also signaling continued investment and cash burn as Shield volumes scale (2025 full-year free cash flow burn was about $233 million).

This could also reflect a broader risk-off rotation after new tariff-related headlines pressured multiple stocks in the session.

Sources:

Guardant Health Investor Relations, StockStory, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GH Insider Trading Activity

$GH insiders have traded $GH stock on the open market 66 times in the past 6 months. Of those trades, 0 have been purchases and 66 have been sales.

Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 4 sales selling 390,565 shares for an estimated $27,238,215.
AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 6 sales selling 100,000 shares for an estimated $10,505,473.
MICHAEL BRIAN BELL (Chief Financial Officer) has made 0 purchases and 12 sales selling 80,362 shares for an estimated $8,288,741.
TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 13 sales selling 73,769 shares for an estimated $7,948,344.
CHRIS FREEMAN (Chief Commercial Officer) has made 0 purchases and 11 sales selling 31,452 shares for an estimated $3,241,621.
IAN T CLARK has made 0 purchases and 3 sales selling 28,611 shares for an estimated $3,066,817.
DARYA CHUDOVA (Chief Technology Officer) has made 0 purchases and 3 sales selling 28,386 shares for an estimated $2,985,111.
JOHN G. SAIA (Chief Legal Officer) sold 8,996 shares for an estimated $865,865
MEDINA MANUEL HIDALGO has made 0 purchases and 5 sales selling 4,915 shares for an estimated $391,280.
KUMUD KALIA (Chief Information Officer) sold 2,000 shares for an estimated $209,204
MUSA TARIQ has made 0 purchases and 4 sales selling 464 shares for an estimated $37,153.
MEGHAN V. JOYCE sold 100 shares for an estimated $6,584
MYRTLE S POTTER has made 0 purchases and 2 sales selling 52 shares for an estimated $3,187.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$GH Hedge Fund Activity

We have seen 281 institutional investors add shares of $GH stock to their portfolio, and 207 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 7,131,895 shares (-78.8%) from their portfolio in Q4 2025, for an estimated $728,451,755
WELLINGTON MANAGEMENT GROUP LLP removed 2,842,566 shares (-87.5%) from their portfolio in Q4 2025, for an estimated $290,339,691
ALLIANCEBERNSTEIN L.P. added 1,761,785 shares (+1262.7%) to their portfolio in Q4 2025, for an estimated $179,948,719
FMR LLC added 1,572,168 shares (+190.7%) to their portfolio in Q4 2025, for an estimated $160,581,239
PRICE T ROWE ASSOCIATES INC /MD/ added 1,414,441 shares (+33.5%) to their portfolio in Q4 2025, for an estimated $144,471,003
POINT72 ASSET MANAGEMENT, L.P. added 1,396,754 shares (+1363.8%) to their portfolio in Q4 2025, for an estimated $142,664,453
DEEP TRACK CAPITAL, LP removed 1,354,086 shares (-32.6%) from their portfolio in Q4 2025, for an estimated $138,306,344

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$GH Congressional Stock Trading

Members of Congress have traded $GH stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $GH stock by members of Congress over the last 6 months:

SENATOR SHELDON WHITEHOUSE purchased up to $15,000 on 11/21.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$GH Analyst Ratings

Wall Street analysts have issued reports on $GH in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/20/2026
Canaccord Genuity issued a "Buy" rating on 12/22/2025
Mizuho issued a "Outperform" rating on 12/17/2025
Evercore ISI Group issued a "Outperform" rating on 10/30/2025
Citigroup issued a "Buy" rating on 10/30/2025
UBS issued a "Buy" rating on 10/30/2025
Barclays issued a "Overweight" rating on 10/30/2025

To track analyst ratings and price targets for $GH, check out Quiver Quantitative's $GH forecast page.

$GH Price Targets

Multiple analysts have issued price targets for $GH recently. We have seen 17 analysts offer price targets for $GH in the last 6 months, with a median target of $130.0.

Here are some recent targets:

Kyle Mikson from Canaccord Genuity set a target price of $135.0 on 02/20/2026
Puneet Souda from Leerink Partners set a target price of $180.0 on 02/20/2026
Dan Brennan from TD Cowen set a target price of $135.0 on 02/20/2026
Mark Massaro from BTIG set a target price of $145.0 on 02/20/2026
Daniel Markowitz from Evercore ISI Group set a target price of $110.0 on 02/20/2026
Casey Woodring from JP Morgan set a target price of $130.0 on 02/20/2026
Patrick Donnelly from Citigroup set a target price of $150.0 on 02/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.